Public Company Healthcare

Amgen

Thousand Oaks, California, United States

Amgen is a global biotechnology company that harnesses biology and technology to discover, develop, manufacture, and commercialize human therapeutics for patients across multiple disease areas, including oncology, inflammatory diseases, and nephrology.

Focus Areas
Biopharmaceuticals, Oncology, Immunology / Inflammatory diseases
Website
amgen.com

Tracked deals

3

3 tracked deals across 2021-2022.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Amgen Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Amgen. 2 2021 1 2022

Supporting Data

Recent Transactions

  • Amgen Acquires ChemoCentryx
    August 4, 2022
    Buyer
    Amgen
    Target
    ChemoCentryx
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Amgen agreed to acquire ChemoCentryx for $52 per share in cash (approximately $3.7 billion enterprise value), gaining TAVNEOS (avacopan), a first-in-class oral therapy for ANCA-associated vasculitis. The deal, unanimously approved by both boards, is intended to strengthen Amgen's inflammation and nephrology portfolio and is expected to close following stockholder and regulatory approvals.

  • Amgen Inc. Acquires Rodeo Therapeutics
    March 30, 2021
    Buyer
    Amgen Inc.
    Target
    Rodeo Therapeutics Corporation
    Industry
    Biotechnology
    Location
    Washington, United States
    Type
    Buyout

    Amgen Inc. has agreed to acquire privately held Rodeo Therapeutics, a Seattle-based biopharmaceutical company focused on small-molecule modulators of prostaglandin biology, including a lead 15-PGDH program. The deal includes a $55 million upfront cash payment plus up to $666 million in potential contingent milestone payments and is intended to expand Amgen's inflammation and tissue-regeneration capabilities.

  • Target RWE Acquires NoviSci Inc.
    January 15, 2021
    Buyer
    Target RWE, Amgen Inc., Norwest Venture Partners, 22C Capital
    Target
    NoviSci, Inc.
    Industry
    Healthcare Services
    Location
    North Carolina, United States
    Type
    Buyout

    Target RWE, a Durham-based real-world evidence solutions company, has acquired NoviSci, Inc., a software analytics and services firm that applies epidemiologic methods and causal inference to health data. Amgen Inc. also made a strategic investment in the combined company, joining existing investors Norwest Venture Partners and 22C Capital to support growth; financial terms were not disclosed.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 2 tracked deals by Amgen. Healthcare Services Buyers & Acquisitions 1 tracked deal by Amgen. Acquisitions in California 1 tracked deal by Amgen. Acquisitions in North Carolina 1 tracked deal by Amgen. Acquisitions in Washington 1 tracked deal by Amgen.

Related articles

Selling a company? Get in front of buyers like Amgen

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →